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EDITORIAL
Transcatheter  aortic  valve  replacement:
A breakthrough  medical  therapy!  The  20-year
odyssey, and  now,  a  10-year  anniversary
Remplacement  valvulaire  aortique  percutané  :  un  traitement  médical
révolutionnaire !  Une  Odyssée  s’étalant  sur  20  ans  et  maintenant  le  10e
anniversaire
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The  concluding  statement  from  a  ﬁrst-in-man  case  report  published  in  Circulation  in  2002
was:  ‘‘Nonsurgical  implantation  of  a  prosthetic  heart  valve  can  be  successfully  achievedProsthetic  heart
valve;
Transcatheter  aortic
with  immediate  and  midterm  hemodynamic  and  clinical  improvement’’  [1].  The  lead
author  of  this  short  manuscript  was  Alain  Cribier,  and  the  procedure  involved  transcatheter
placement  of  a  bioprosthetic  aortic  valve  in  a  desperately  ill  man  with  critical  aortic  steno-valve replacement
MOTS  CLÉS
Prothèse  valvulaire  ;
Remplacement
valvulaire  aortique
percutané
sis  (AS)  and  no  therapy  alternatives.  At  the  time,  it  was  impossible  to  predict  the  future  of
this  new  medical  therapy,  which  at  the  same  time  appeared  both  reckless  and  revolution-
ary.  In  retrospect,  10  years  later,  this  humble  concluding  statement  laid  the  foundation  for
a  medical  breakthrough  that  has  altered  the  landscape  of  cardiovascular  medicine.  The
odyssey  and  the  anniversary  of  transcatheter  aortic  valve  replacement  (TAVR)  deserve  our
attention  and  careful  reﬂection.
To  qualify  as  an  important  medical  breakthrough,  a  new  therapy  must  fulﬁl  ﬁve  criteria:
• address  an  important  unmet  clinical  need  for  a  common  disease;
• apply  innovative  technology  solutions  that  are  disruptive  in  nature;
• have  validated  incremental  therapy  beneﬁt  via  rigorous  evidence-based  medicine  stan-
dards;
• can  be  generalized  to  the  practising  medical  community  at  large;
• stimulate  change  in  the  milieu  and  pattern  of  medical  practice  beyond  the  narrow
conﬁnes  of  the  procedure  itself.
There  is  little  doubt  that  TAVR,  as  currently  practised  around  the  world,  addresses  an
unmet  clinical  need  for  a  common  disease.  The  prevalence  of  AS  in  people  over  the  age  of
75  years  is  approximately  5%,  and  with  a  rising  aging  population,  the  optimal  treatment  of
calciﬁc  AS  is  becoming  an  important  global  healthcare  concern.  Over  the  past  decade,  the
medical  community  has  ﬁnally  acknowledged  that  AS  in  the  elderly,  especially  in  patients
with  threatening  co-existing  illnesses,  is  both  under-diagnosed  and  under-treated.  At  least
one-third  of  patients  with  severe  AS  and  cardiac  symptoms  do  not  currently  undergo  con-
ventional  surgical  aortic  valve  replacement  [2,3].  This  is  not  merely  a  resource  allocation
issue  affecting  certain  geographies,  but  rather  is  a  general  concern  in  all  clinical  practice
environments  in  all  parts  of  the  world.  Simply  stated,  less-invasive  treatment  strategies
are  necessary  to  successfully  treat  elderly  AS  patients  with  signiﬁcant  co-morbidities.
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As  an  innovative  medical  technology,  TAVR  is  among
 handful  of  medical  therapies  to  emerge  in  the  past
ecade that  promise  to  fundamentally  change  treatment
ractice. The  mere  concept  that  a  diseased  native  aor-
ic valve  can  be  replaced  and  functionally  transplanted
ith a  new  bioprosthetic  valve  using  solely  percutaneous
echniques strains  the  imagination  of  even  the  most  cre-
tive thinkers.  Yet,  the  essential  components  of  TAVR  are
argely iterative  and  derive  from  predicate  advances  in
urgery and  interventional  cardiology.  The  vision  of  a  valve
n a  catheter  was  introduced  more  than  50  years  ago
y Davies  [4]  and  was  later  reﬁned  by  Andersen  et  al.
n seminal  animal  investigations  [5].  Mechanical  dilatation
f stenosed  aortic  valves  was  pioneered  by  Cribier  and
is colleagues  in  1986  [6]  but  was  soon  discarded  due  to
arly complications  and  frequent  recurrences.  Soon  there-
fter, improved  durability  of  bioprosthetic  surgical  valves
nd the  emergence  of  permanent  metallic  vascular  scaf-
olds (endovascular  prostheses  or  ‘‘stents’’)  offered  new
ossibilities. Nevertheless,  these  fundamental  components
equired creative  integration  into  prototype  devices.  The
nal products  were  a  remarkable  technology  achievement
 catheter-based  balloon-expandable  (or  self-expanding)
upport frames  attached  to  and  incorporating  bioprosthetic
alves, which  could  be  delivered  and  released  remotely  and
redictably to  target  sites  in  a  beating  heart.  Still,  these
echnology marvels  required  the  creative  genius  and  persis-
ence of  ﬁrst  Bonhoeffer  et  al.  in  2000  [7]  and  then  Cribier
t al.  in  2002  [1]  to  bring  such  devices  into  the  clinical  arena.
AVR truly  qualiﬁes  as  a  ‘‘disruptive’’  technology,  in  that  a
ifferent value  proposition  for  AS  therapy  was  introduced,
hich is  faster,  simpler  and  more  generally  applicable  to
atients around  the  world.
The  acceptance  of  TAVR  as  a  legitimate  medical  ther-
py demanded  careful  evidence-based  medicine  validation.
 radical  (and  expensive)  technology  applied  in  elderly  co-
orbid patients  naturally  evoked  controversy,  scepticism
nd overt  criticism.  Early  clinical  trials  in  this  ﬁeld  were  self-
eported single  or  multi-institutional  reports,  which  were  at
nce both  clarifying  and  confusing.  In  defence  of  these  ini-
ial clinical  research  efforts,  it  was  problematic  to  subject  a
apidly evolving  technology  and  procedure  to  overly  aggres-
ive research  scrutiny.  Within  several  years,  stabilization  of
he TAVR  platforms  and  improved  research  methodologies
8] led  to  the  development  of  carefully  conducted  clinical
rials in  appropriate  patient  subsets  [9,10].  The  Placement
f Aortic  Transcatheter  Valves  (PARTNER)  randomized  trials
9,10] deﬁnitively  established  TAVR  as  a  new  standard-of-
are in  severe  AS  patients  without  surgical  options  and  as
n alternative  to  surgery  in  high-risk  patients.  This  commit-
ent to  the  highest  principles  of  evidence-based  medicine  is
mbued in  innumerable  ongoing  international  TAVR  research
rogrammes and  should  become  a  vital  guidepost  as  TAVR  is
arefully and  appropriately  integrated  into  clinical  practice.
Since  the  introduction  of  TAVR  to  the  European  com-
unity in  2007,  there  has  been  a  dramatic  40%  compound
nnual growth  rate,  such  that  by  the  end  of  2011  almost
0% of  all  aortic  valve  replacement  procedures  in  some
arge European  countries  were  performed  via  transcatheter
ethods. Careful  physician  and  site  training  programmes
ave been  developed,  incorporating  didactic  sessions,  medi-
al simulation  techniques,  case  presentations  and  on-site
s
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roctoring  to  ensure  the  disciplined  dispersion  of  this
ormidable new  technology.  Thus  far,  employing  these  train-
ng  algorithms,  almost  50,000  TAVR  procedures  have  been
erformed in  more  than  500  clinical  centres  around  the
orld. Concerns  regarding  the  possibility  of  deteriorat-
ng outcomes,  downward  ‘‘risk  drift’’  in  less  well-deﬁned
atient subgroups,  and  overly  enthusiastic  expansion  to  less
ualiﬁed centres  are  being  carefully  scrutinized  by  societies
nd government  agencies  [11].
Perhaps  the  most  important  contribution  of  TAVR  to  the
dvancement of  medicine  is  not  the  technology  or  the
linical outcomes,  but  rather  a  unique  culture  that  has
risen. The  territorial  practice  of  subspecialty  medicine  has
een  replaced  by  a  disease-state  model  requiring  multidis-
iplinary physician  collaboration.  The  ‘‘Heart  Valve  Team’’
pproach to  TAVR  practice  has  joined  surgical,  interven-
ional and  imaging  specialists  in  the  best  interest  of  patient
are. This  multidisciplinary  group  dynamic  stimulated  by
AVR will  dissolve  previous  barriers  and  likely  foster  a
onstructive change  in  future  practice  patterns  in  other  sub-
pecialties. Even  the  procedural  milieu  is  being  modiﬁed
 a  shared  so-called  ‘‘hybrid’’  environment,  which  allows
he seamless  integration  of  interventional  and  surgical  ther-
pies. This  integration  also  encompasses  a  multimodality
maging approach  to  assist  with  diagnosis,  case  planning
nd intraprocedural  decision-making.  Thus,  TAVR  by  virtue
f its  complexity  and  novelty  has  challenged  the  foun-
ations of  medical  practice,  and  ‘‘won’’.  We  are  now  a
hysician community  combining  advanced  skill  sets  in  the
ost advantageous  treatment  environments,  resulting  in  the
chievement of  synergistic  clinical  outcomes.
By  all  criteria,  TAVR  is  clearly  a  ‘‘breakthrough  technol-
gy’’ and  medicine  owes  a  great  debt  to  the  passionate
nd humble  pioneer,  Alain  Cribier,  whose  relentless  pursuit
f a  dream  culminated  in  a  life-saving  reality.  This  special
dition of  Archives  of  Cardiovascular  Diseases  celebrates
ribier’s ‘‘triumph  of  the  human  spirit’’  — his  pilgrimage
o shepherd  TAVR  from  a prototype  device  concept,  through
ears of  animal  experiments,  to  the  early  courageous  clin-
cal cases,  which  were  both  exhilarating  and  agonizing,  to
urrent reﬁnements  in  technology  and  procedures  that  have
esulted in  an  extraordinary  medical  advance.  His  friends
nd colleagues,  many  now  important  thought-leaders,  have
hared their  expertise  to  craft  a  special  celebratory  issue
n his  honour.  The  introductory  manuscript,  authored  by
ribier himself,  is  a  historical  tour  of  the  20-year  odyssey
ighlighted by  many  personal  reﬂections.  This  is  followed
y a  detailed  account  from  a  cherished  colleague,  Helene
ltchaninoff, describing  clinical  results  in  Rouen,  comparing
revious and  new  transfemoral  TAVR  systems.  John  Webb,
qual parts  disciple  and  pioneer,  provides  a  technology
our-de-force of  evolutionary  changes  in  devices,  deliv-
ry systems  and  access  routes.  The  future  vision  of  TAVR
 simpler  and  safer  —  that  is,  better  devices  and  fewer
omplications, is  articulated  by  a  European  leader  in  valvu-
ar heart  disease,  Alec  Vahanian.  Surgical  perspectives  and  a
eview of  transapical  TAVR  experiences  are  thoughtfully  dis-
ussed by  Thomas  Walther  and  Pierre-Yves  Litzler.  Finally,
n a  tribute  to  the  ‘‘next  generation’’  of  interventional
cientists, the  topics  of  United  States  TAVR  experiences,
atient selection  and  biomedical  engineering  perspectives
re reviewed  by  accomplished  junior  academicians.
[[TAVR  — a breakthrough  medical  therapy  
The  10-year  anniversary  of  the  ﬁrst  TAVR  implant  in
Rouen, France,  by  Alain  Cribier  and  his  team  represents  a
landmark event  in  the  history  of  medicine.  During  a  featured
lecture at  the  Transcatheter  Cardiovascular  Therapeutics
symposium in  2011  in  San  Francisco,  Alain  Cribier  quoted
Andre Gidé  as  follows:  ‘‘One  doesn’t  discover  new  lands
without consenting  to  lose  sight  of  the  shore  for  a  very
long time’’.  At  this  momentous  occasion,  all  of  medicine
would agree  that  Alain  Cribier  has  discovered  new  lands  with
an indomitable  spirit  and  a  special  vision  that  gazes  across
oceans —  in  the  noble  pursuit  of  satisfying  his  passion  for
helping patients.
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